{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:00:20Z","timestamp":1780063220957,"version":"3.54.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Lundbeck Foundation Initiative for Integrative Psychiatric Research","award":["R155-2014-1724"],"award-info":[{"award-number":["R155-2014-1724"]}]},{"name":"The Lundbeck Foundation Initiative for Integrative Psychiatric Research","award":["R155-2014-1724"],"award-info":[{"award-number":["R155-2014-1724"]}]},{"name":"Magna Graecia University Fundation","award":["2019-256"],"award-info":[{"award-number":["2019-256"]}]},{"name":"Magna Graecia University Foundation","award":["2019-256"],"award-info":[{"award-number":["2019-256"]}]},{"name":"The Independent Research Fund Denmark","award":["7025-00078B"],"award-info":[{"award-number":["7025-00078B"]}]},{"name":"The Independent Research Fund Denmark","award":["7025-00078B"],"award-info":[{"award-number":["7025-00078B"]}]},{"name":"The Lundbeck Foundation","award":["R268-2016-3925 and R278-2018-1411"],"award-info":[{"award-number":["R268-2016-3925 and R278-2018-1411"]}]},{"name":"The Lundbeck Foundation","award":["R268-2016-3925 and R278-2018-1411"],"award-info":[{"award-number":["R268-2016-3925 and R278-2018-1411"]}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR070276 and R01 AR072694"],"award-info":[{"award-number":["R01 AR070276 and R01 AR072694"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR070276, R01 AR072694"],"award-info":[{"award-number":["R01 AR070276, R01 AR072694"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000778","name":"U.S. Department of Labor","doi-asserted-by":"publisher","award":["RO1 AR32599 and CTSA-UL1TR002489"],"award-info":[{"award-number":["RO1 AR32599 and CTSA-UL1TR002489"]}],"id":[{"id":"10.13039\/100000778","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007197","name":"U.S. Public Health Service","doi-asserted-by":"publisher","award":["RO1 AR32599 and CTSA-UL1TR002489"],"award-info":[{"award-number":["RO1 AR32599 and CTSA-UL1TR002489"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["538-2013-8864"],"award-info":[{"award-number":["538-2013-8864"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["538-2013-8864"],"award-info":[{"award-number":["538-2013-8864"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bullous pemphigoid (BP) is an autoimmune blistering skin disease that takes a profound physical and mental toll on those affected. The aim of the study was to investigate the bidirectional association between BP and all bullous disorders (ABD) with a broad array of psychiatric disorders, exploring the influence of prescribed medications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This nationwide, register-based cohort study encompassed 6,470,450 individuals born in Denmark and alive from 1994 to 2016. The hazard ratios (HRs) of a subsequent psychiatric disorder in patients with BP\/ABD and the reverse exposure and outcome were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Several psychiatric disorders were associated with increased risk of subsequent BP (4.18-fold for intellectual disorders, 2.32-fold for substance use disorders, 2.01-fold for schizophrenia and personality disorders, 1.92\u20131.85-1.49-fold increased risk for organic disorders, neurotic and mood disorders), independent of psychiatric medications. The association between BP and subsequent psychiatric disorders was not significant after adjusting for BP medications, except for organic disorders (HR 1.27, CI 1.04\u20131.54). Similar results emerged with ABD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Psychiatric disorders increase the risk of a subsequent diagnosis of BP\/ABD independent of medications, whereas medications used for the treatment of BP\/ABD appear to account for the subsequent onset of psychiatric disorders. Clinically, an integrated approach attending to both dermatological and psychiatric symptoms is recommended, and dermatologists should remain vigilant for early symptoms of psychiatric disorders to decrease mental health comorbidity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-020-02810-x","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T11:02:57Z","timestamp":1597921377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Psychiatric comorbidity in individuals with bullous pemphigoid and all bullous disorders in the Danish national registers"],"prefix":"10.1186","volume":"20","author":[{"given":"Marianna","family":"Rania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liselotte Vogdrup","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Eriksen","family":"Benros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7772-3264","authenticated-orcid":false,"given":"Cynthia M.","family":"Bulik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"2810_CR1","volume-title":"Pemphigus and pemphigoid","author":"W Lever","year":"1965","unstructured":"Lever W. In: Charles C, Thomas P, editors. Pemphigus and pemphigoid. Springfield: Charles C Thomas, Publisher; 1965."},{"key":"2810_CR2","volume-title":"Fitzpatrick's dermatology","author":"DA Culton","year":"2019","unstructured":"Culton DA, Liu Z, Diaz LA. Bullous Pemphigoid. In: Kang S, Amagai M, Bruckner AL, et al., editors. Fitzpatrick's dermatology. 9th ed. New York: McGraw-Hill Education; 2019.","edition":"9"},{"key":"2810_CR3","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1610-0387.2008.06976.x","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram F, Brocker EB, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7:434\u201340. https:\/\/doi.org\/10.1111\/j.1610-0387.2008.06976.x.","journal-title":"J Dtsch Dermatol Ges"},{"key":"2810_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","volume":"71","author":"KE Brick","year":"2014","unstructured":"Brick KE, Weaver CH, Lohse CM, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71:92\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2014.02.030.","journal-title":"J Am Acad Dermatol"},{"key":"2810_CR5","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1111\/bjd.13189","volume":"171","author":"AK F\u00f6rsti","year":"2014","unstructured":"F\u00f6rsti AK, Jokelainen J, Timonen M, et al. Increasing incidence of bullous pemphigoid in northern Finland: a retrospective database study in Oulu University hospital. Br J Dermatol. 2014;171:1223\u20136.","journal-title":"Br J Dermatol"},{"key":"2810_CR6","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","volume":"153","author":"VS Gudi","year":"2005","unstructured":"Gudi VS, White MI, Cruickshank N, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland. Br J Dermatol. 2005;153:424\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06662.x.","journal-title":"Br J Dermatol"},{"key":"2810_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","volume":"161","author":"G Marazza","year":"2009","unstructured":"Marazza G, Pham HC, Scharer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: A 2-year prospective study. Br J Dermatol. 2009;161:861\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09300.x.","journal-title":"Br J Dermatol"},{"key":"2810_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00403-017-1778-4","volume":"309","author":"K Thorslund","year":"2017","unstructured":"Thorslund K, Seifert O, Nilz\u00e9n K, et al. Incidence of bullous pemphigoid in Sweden 2005\u20132012: a nationwide population-based cohort study of 3761 patients. Arch Dermatol Res. 2017;309:721\u20137.","journal-title":"Arch Dermatol Res"},{"key":"2810_CR9","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","volume":"337","author":"SM Langan","year":"2008","unstructured":"Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: Population based cohort study. Bmj. 2008;337:a180. https:\/\/doi.org\/10.1136\/bmj.a180.","journal-title":"Bmj"},{"key":"2810_CR10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/s0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381:320\u201332. https:\/\/doi.org\/10.1016\/s0140-6736(12)61140-4.","journal-title":"Lancet"},{"key":"2810_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1590\/abd1806-4841.20164935","volume":"91","author":"A Kouris","year":"2016","unstructured":"Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study. An Bras Dermatol. 2016;91:601\u20133. https:\/\/doi.org\/10.1590\/abd1806-4841.20164935.","journal-title":"An Bras Dermatol"},{"key":"2810_CR12","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/jdv.15062","volume":"32","author":"EQ Wang","year":"2018","unstructured":"Wang EQ, Radjenovic M, Castrillon MA, et al. The effect of autoimmune blistering diseases on work productivity. J Eur Acad Dermatol Venereol. 2018;32:1959\u201366. https:\/\/doi.org\/10.1111\/jdv.15062.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2810_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2340\/00015555-2930","volume":"99","author":"K Kridin","year":"2019","unstructured":"Kridin K, Shihade W, Bergman R. Mortality in patients with bullous pemphigoid: A retrospective cohort study, systematic review and meta-analysis. Acta Derm Venereol. 2019;99:72\u20137. https:\/\/doi.org\/10.2340\/00015555-2930.","journal-title":"Acta Derm Venereol"},{"key":"2810_CR14","doi-asserted-by":"publisher","unstructured":"Stanley JR, Hawley-Nelson P, Yuspa SH, et al. Characterization of bullous pemphigoid antigen: A unique basement membrane protein of stratified squamous epithelia. Cell. 1981; 24: 897\u2013903. DOI: https:\/\/doi.org\/https:\/\/doi.org\/10.1016\/0092-8674(81)90115-X.","DOI":"10.1016\/0092-8674(81)90115-X"},{"key":"2810_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/1523-1747.ep12616580","volume":"99","author":"GJ Giudice","year":"1992","unstructured":"Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol. 1992;99:243\u201350. https:\/\/doi.org\/10.1111\/1523-1747.ep12616580.","journal-title":"J Invest Dermatol"},{"key":"2810_CR16","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1172\/JCI116856","volume":"92","author":"Z Liu","year":"1993","unstructured":"Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92:2480\u20138. https:\/\/doi.org\/10.1172\/JCI116856.","journal-title":"J Clin Invest"},{"key":"2810_CR17","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","volume":"138","author":"L Lin","year":"2018","unstructured":"Lin L, Hwang BJ, Culton DA, et al. Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid. J Invest Dermatol. 2018;138:1032\u201343. https:\/\/doi.org\/10.1016\/j.jid.2017.11.031.","journal-title":"J Invest Dermatol"},{"key":"2810_CR18","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1365-2133.2011.10641.x","volume":"166","author":"AO Sepp\u00e4nen","year":"2012","unstructured":"Sepp\u00e4nen AO. Both bullous pemphigoid antigens are expressed in the central nervous system. Br J Dermatol. 2012;166:683\u20134. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10641.x.","journal-title":"Br J Dermatol"},{"key":"2810_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.brainres.2007.04.073","volume":"1158","author":"A Seppanen","year":"2007","unstructured":"Seppanen A, Suuronen T, Hofmann SC, et al. Distribution of collagen XVII in the human brain. Brain Res. 2007;1158:50\u20136. https:\/\/doi.org\/10.1016\/j.brainres.2007.04.073.","journal-title":"Brain Res"},{"key":"2810_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0151-9638(06)70935-8","volume":"133","author":"N Foureur","year":"2006","unstructured":"Foureur N, Mignot S, Senet P, et al. Correlation between the presence of type-2 anti-pemphigoid antibodies and dementia in elderly subjects with no clinical signs of pemphigoid. Ann Dermatol Venereol. 2006;133:439\u201343.","journal-title":"Ann Dermatol Venereol"},{"key":"2810_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2133.2004.06338.x","volume":"152","author":"E Laffitte","year":"2005","unstructured":"Laffitte E, Burkhard PR, Fontao L, et al. Bullous pemphigoid antigen 1 isoforms: Potential new target autoantigens in multiple sclerosis? Br J Dermatol. 2005;152:537\u201340. https:\/\/doi.org\/10.1111\/j.1365-2133.2004.06338.x.","journal-title":"Br J Dermatol"},{"key":"2810_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000315393","volume":"57","author":"J Chen","year":"2011","unstructured":"Chen J, Li L, Chen J, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology. 2011;57:211\u20136. https:\/\/doi.org\/10.1159\/000315393.","journal-title":"Gerontology"},{"key":"2810_CR23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1684\/ejd.2017.3066","volume":"27","author":"N Milani-Nejad","year":"2017","unstructured":"Milani-Nejad N, Zhang M, Kaffenberger J. The association between bullous pemphigoid and neurological disorders: A systematic review. Eur J Dermatol. 2017;27:472\u201381. https:\/\/doi.org\/10.1684\/ejd.2017.3066.","journal-title":"Eur J Dermatol"},{"key":"2810_CR24","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/jdv.13660","volume":"30","author":"YC Lai","year":"2016","unstructured":"Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30:2007\u201315. https:\/\/doi.org\/10.1111\/jdv.13660.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2810_CR25","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1111\/j.1365-2133.2009.09122.x","volume":"160","author":"L Li","year":"2009","unstructured":"Li L, Chen J, Wang B, et al. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol. 2009;160:1343\u20135. https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09122.x.","journal-title":"Br J Dermatol"},{"key":"2810_CR26","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","volume":"165","author":"YJ Chen","year":"2011","unstructured":"Chen YJ, Wu CY, Lin MW, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011;165:593\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10386.x.","journal-title":"Br J Dermatol"},{"key":"2810_CR27","doi-asserted-by":"publisher","first-page":"37125","DOI":"10.1038\/srep37125","volume":"6","author":"A-K F\u00f6rsti","year":"2016","unstructured":"F\u00f6rsti A-K, Jokelainen J, Ansakorpi H, et al. Psychiatric and neurological disorders are associated with bullous pemphigoid \u2013 a nationwide Finnish Care Register study. Sci Rep. 2016;6:37125. https:\/\/doi.org\/10.1038\/srep37125.","journal-title":"Sci Rep"},{"key":"2810_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjd.14821","volume":"176","author":"Z Ren","year":"2017","unstructured":"Ren Z, Hsu D, Brieva J, et al. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the USA. Br J Dermatol. 2017;176:87\u201399.","journal-title":"Br J Dermatol"},{"key":"2810_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","volume":"131","author":"S Bastuji-Garin","year":"2011","unstructured":"Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case\u2013control study. J Invest Dermatol. 2011;131:637\u201343.","journal-title":"J Invest Dermatol"},{"key":"2810_CR30","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1590\/abd1806-4841.20142516","volume":"89","author":"VB Teixeira","year":"2014","unstructured":"Teixeira VB, Cabral R, Brites MM, et al. Bullous pemphigoid and comorbidities: a case-control study in Portuguese patients. An Bras Dermatol. 2014;89:274\u20138.","journal-title":"An Bras Dermatol"},{"key":"2810_CR31","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00296-013-2750-z","volume":"33","author":"SD Bhangle","year":"2013","unstructured":"Bhangle SD, Kramer N, Rosenstein ED. Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus. Rheumatol Int. 2013;33:1923\u201332. https:\/\/doi.org\/10.1007\/s00296-013-2750-z.","journal-title":"Rheumatol Int"},{"key":"2810_CR32","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0091217415612735","volume":"50","author":"M Gable","year":"2015","unstructured":"Gable M, Depry D. Sustained corticosteroid- induced mania and psychosis despite cessation: A case study and brief literature review. Int J Psychiatry Med. 2015;50:398\u2013404. https:\/\/doi.org\/10.1177\/0091217415612735.","journal-title":"Int J Psychiatry Med"},{"key":"2810_CR33","first-page":"122","volume":"151","author":"S Caccavale","year":"2016","unstructured":"Caccavale S, Mea EE, La Montagna M. Bullous pemphigoid induced by escitalopram in a patient with depression. G Ital Dermatol Venereol. 2016;151:122\u20133.","journal-title":"G Ital Dermatol Venereol"},{"key":"2810_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1046\/j.1365-2133.1999.03130.x","volume":"141","author":"S Rault","year":"1999","unstructured":"Rault S, Grosieux-Dauger C, Verraes S, et al. Bullous pemphigoid induced by fluoxetine. Br J Dermatol. 1999;141:755\u20136. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.03130.x.","journal-title":"Br J Dermatol"},{"key":"2810_CR35","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bjd.15195","volume":"176","author":"CW Tan","year":"2017","unstructured":"Tan CW, Pang Y, Sim B, et al. The association between drugs and bullous pemphigoid. Br J Dermatol. 2017;176:549\u201351. https:\/\/doi.org\/10.1111\/bjd.15195.","journal-title":"Br J Dermatol"},{"key":"2810_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jaad.2019.02.017","volume":"81","author":"O Varpuluoma","year":"2019","unstructured":"Varpuluoma O, Jokelainen J, Forsti AK, et al. Drugs used for neurologic and psychiatric conditions increase the risk for bullous pemphigoid: A case-control study. J Am Acad Dermatol. 2019;81:250\u20133. https:\/\/doi.org\/10.1016\/j.jaad.2019.02.017.","journal-title":"J Am Acad Dermatol"},{"key":"2810_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/1403494810387965","volume":"39","author":"CB Pedersen","year":"2011","unstructured":"Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39:22\u20135. https:\/\/doi.org\/10.1177\/1403494810387965.","journal-title":"Scand J Public Health"},{"key":"2810_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/1403494811401482","volume":"39","author":"E Lynge","year":"2011","unstructured":"Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39:30\u20133. https:\/\/doi.org\/10.1177\/1403494811401482.","journal-title":"Scand J Public Health"},{"key":"2810_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1177\/1403494810395825","volume":"39","author":"O Mors","year":"2011","unstructured":"Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health. 2011;39:54\u20137. https:\/\/doi.org\/10.1177\/1403494810395825.","journal-title":"Scand J Public Health"},{"key":"2810_CR40","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1093\/schbul\/sby015.217","volume":"44","author":"OP Ripoll","year":"2018","unstructured":"Ripoll OP, Pedersen C, Agerbo E, et al. O5.3. A comprehensive nationwide study of comorbidity within treated mental disorders\u2014a Danish register-based study. Schizophr Bull. 2018;44:S87.","journal-title":"Schizophr Bull"},{"key":"2810_CR41","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1403494810394717","volume":"39","author":"HW Kildemoes","year":"2011","unstructured":"Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39:38\u201341. https:\/\/doi.org\/10.1177\/1403494810394717.","journal-title":"Scand J Public Health"},{"key":"2810_CR42","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 2019, https:\/\/www.whocc.no\/filearchive\/publications\/2020_guidelines_web.pdf."},{"key":"2810_CR43","volume-title":"Stata Statistical Software: Release 15","author":"StataCorp","year":"2017","unstructured":"StataCorp. Stata Statistical Software: Release 15. College Station: StataCorp LP; 2017."},{"key":"2810_CR44","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1177\/1352458510369146","volume":"16","author":"A Langer-Gould","year":"2010","unstructured":"Langer-Gould A, Albers KB, Van Den Eeden SK, et al. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler. 2010;16:855\u201361. https:\/\/doi.org\/10.1177\/1352458510369146.","journal-title":"Mult Scler"},{"key":"2810_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/jid.2010.357","volume":"131","author":"SM Langan","year":"2011","unstructured":"Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: A population-based case-control study. J Invest Dermatol. 2011;131:631\u20136. https:\/\/doi.org\/10.1038\/jid.2010.357.","journal-title":"J Invest Dermatol"},{"key":"2810_CR46","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.jaad.2014.07.052","volume":"71","author":"KE Brick","year":"2014","unstructured":"Brick KE, Weaver CH, Savica R, et al. A population-based study of the association between bullous pemphigoid and neurologic disorders. J Am Acad Dermatol. 2014;71:1191\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.052.","journal-title":"J Am Acad Dermatol"},{"key":"2810_CR47","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1111\/bjd.15405","volume":"176","author":"L Kibsgaard","year":"2017","unstructured":"Kibsgaard L, Rasmussen M, Lamberg A, et al. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol. 2017;176:1486\u201391.","journal-title":"Br J Dermatol"},{"key":"2810_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1161\/strokeaha.110.596361","volume":"42","author":"YW Yang","year":"2011","unstructured":"Yang YW, Chen YH, Xirasagar S, et al. Increased risk of stroke in patients with bullous pemphigoid: A population-based follow-up study. Stroke. 2011;42:319\u201323. https:\/\/doi.org\/10.1161\/strokeaha.110.596361.","journal-title":"Stroke"},{"key":"2810_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11920-019-1050-z","volume":"21","author":"PF Buckley","year":"2019","unstructured":"Buckley PF. Neuroinflammation and schizophrenia. Curr Psychiatry Rep. 2019;21:72. https:\/\/doi.org\/10.1007\/s11920-019-1050-z.","journal-title":"Curr Psychiatry Rep"},{"key":"2810_CR50","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2174\/1570159x15666170828170921","volume":"16","author":"JV Pinto","year":"2018","unstructured":"Pinto JV, Passos IC, Librenza-Garcia D, et al. Neuron-glia interaction as a possible pathophysiological mechanism of bipolar disorder. Curr Neuropharmacol. 2018;16:519\u201332. https:\/\/doi.org\/10.2174\/1570159x15666170828170921.","journal-title":"Curr Neuropharmacol"},{"key":"2810_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.biopsycho.2015.09.003","volume":"112","author":"JR Fanning","year":"2015","unstructured":"Fanning JR, Lee R, Gozal D, et al. Childhood trauma and parental style: Relationship with markers of inflammation, oxidative stress, and aggression in healthy and personality disordered subjects. Biol Psychol. 2015;112:56\u201365. https:\/\/doi.org\/10.1016\/j.biopsycho.2015.09.003.","journal-title":"Biol Psychol"},{"key":"2810_CR52","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s12640-012-9334-7","volume":"23","author":"KH Clark","year":"2013","unstructured":"Clark KH, Wiley CA, Bradberry CW. Psychostimulant abuse and neuroinflammation: Emerging evidence of their interconnection. Neurotox Res. 2013;23:174\u201388. https:\/\/doi.org\/10.1007\/s12640-012-9334-7.","journal-title":"Neurotox Res"},{"key":"2810_CR53","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","volume":"28","author":"PG Stavropoulos","year":"2014","unstructured":"Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: A review of the literature. J Eur Acad Dermatol Venereol. 2014;28:1133\u201340. https:\/\/doi.org\/10.1111\/jdv.12366.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2810_CR54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","volume":"149","author":"A Lloyd-Lavery","year":"2013","unstructured":"Lloyd-Lavery A, Chi C-C, Wojnarowska F, et al. The associations between bullous pemphigoid and drug use: a UK case-control study. JAMA Dermatol. 2013;149:58\u201362. https:\/\/doi.org\/10.1001\/2013.jamadermatol.376.","journal-title":"JAMA Dermatol"},{"key":"2810_CR55","first-page":"562","volume":"5","author":"JJ Lee","year":"2006","unstructured":"Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: Case report and review of literature. J Drugs Dermatol. 2006;5:562\u20134.","journal-title":"J Drugs Dermatol"},{"key":"2810_CR56","first-page":"56","volume":"129","author":"AB Modeste","year":"2002","unstructured":"Modeste AB, Cordel N, Courville P, et al. Bullous pemphigoid induced by spironolactone. Ann Dermatol Venereol. 2002;129:56\u20138.","journal-title":"Ann Dermatol Venereol"},{"key":"2810_CR57","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1176\/ajp.153.5.735a","volume":"153","author":"C Wijeratne","year":"1996","unstructured":"Wijeratne C, Webster P. Risperidone and bullous pemphigoid. Am J Psychiatry. 1996;153:735. https:\/\/doi.org\/10.1176\/ajp.153.5.735a.","journal-title":"Am J Psychiatry"},{"key":"2810_CR58","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","volume":"172","author":"C Feliciani","year":"2015","unstructured":"Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: The European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172:867\u201377. https:\/\/doi.org\/10.1111\/bjd.13717.","journal-title":"Br J Dermatol"},{"key":"2810_CR59","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.sapharm.2015.05.012","volume":"12","author":"S Kusljic","year":"2016","unstructured":"Kusljic S, Manias E, Gogos A. Corticosteroid-induced psychiatric disturbances: It is time for pharmacists to take notice. Res Soc Adm Pharm. 2016;12:355\u201360. https:\/\/doi.org\/10.1016\/j.sapharm.2015.05.012.","journal-title":"Res Soc Adm Pharm"},{"key":"2810_CR60","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1440-1819.2011.02260.x","volume":"65","author":"HA Kenna","year":"2011","unstructured":"Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: Review with case report. Psychiatry Clin Neurosci. 2011;65:549\u201360. https:\/\/doi.org\/10.1111\/j.1440-1819.2011.02260.x.","journal-title":"Psychiatry Clin Neurosci"},{"key":"2810_CR61","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/0163-8343(96)00005-9","volume":"18","author":"A Stoudemire","year":"1996","unstructured":"Stoudemire A, Anfinson T, Edwards J. Corticosteroid-induced delirium and dependency. Gen Hosp Psychiatry. 1996;18:196\u2013202. https:\/\/doi.org\/10.1016\/0163-8343(96)00005-9.","journal-title":"Gen Hosp Psychiatry"},{"key":"2810_CR62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00296-007-0410-x","volume":"28","author":"S Appenzeller","year":"2008","unstructured":"Appenzeller S, Cendes F, Costallat LT. Acute psychosis in systemic lupus erythematosus. Rheumatol Int. 2008;28:237\u201343. https:\/\/doi.org\/10.1007\/s00296-007-0410-x.","journal-title":"Rheumatol Int"},{"key":"2810_CR63","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1192\/bjp.162.4.549","volume":"162","author":"RS Mullen","year":"1993","unstructured":"Mullen RS, Romans-Clarkson SE. Behavioural sensitisation and steroid-induced psychosis. Br J Psychiatry. 1993;162:549\u201351. https:\/\/doi.org\/10.1192\/bjp.162.4.549.","journal-title":"Br J Psychiatry"},{"key":"2810_CR64","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4088\/jcp.v61n0404","volume":"61","author":"K Wada","year":"2000","unstructured":"Wada K, Yamada N, Suzuki H, et al. Recurrent cases of corticosteroid-induced mood disorder: Clinical characteristics and treatment. J Clin Psychiatry. 2000;61:261\u20137. https:\/\/doi.org\/10.4088\/jcp.v61n0404.","journal-title":"J Clin Psychiatry"},{"key":"2810_CR65","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/s1081-1206(10)61756-5","volume":"92","author":"SH Bolanos","year":"2004","unstructured":"Bolanos SH, Khan DA, Hanczyc M, et al. Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann Allergy Asthma Immunol. 2004;92:500\u20135. https:\/\/doi.org\/10.1016\/s1081-1206(10)61756-5.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2810_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4088\/pcc.v03n0104","volume":"3","author":"ES Brown","year":"2001","unstructured":"Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry. 2001;3:17\u201321. https:\/\/doi.org\/10.4088\/pcc.v03n0104.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"2810_CR67","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0165-0327(83)90022-8","volume":"5","author":"DA Lewis","year":"1983","unstructured":"Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord. 1983;5:319\u201332. https:\/\/doi.org\/10.1016\/0165-0327(83)90022-8.","journal-title":"J Affect Disord"},{"key":"2810_CR68","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.psc.2013.08.001","volume":"36","author":"R Aziz","year":"2013","unstructured":"Aziz R, Steffens DC. What are the causes of late-life depression? Psychiatr Clin North Am. 2013;36:497\u2013516. https:\/\/doi.org\/10.1016\/j.psc.2013.08.001.","journal-title":"Psychiatr Clin North Am"},{"key":"2810_CR69","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/fampra\/cmx018","volume":"34","author":"F Holvast","year":"2017","unstructured":"Holvast F, van Hattem BA, Sinnige J, et al. Late-life depression and the association with multimorbidity and polypharmacy: A cross-sectional study. Fam Pract. 2017;34:539\u201345. https:\/\/doi.org\/10.1093\/fampra\/cmx018.","journal-title":"Fam Pract"},{"key":"2810_CR70","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/s0889-8529(02)00008-7","volume":"31","author":"B Richter","year":"2002","unstructured":"Richter B, Neises G, Clar C. Glucocorticoid withdrawal schemes in chronic medical disorders. A systematic review. Endocrinol Metab Clin N Am. 2002;31:751\u201378. https:\/\/doi.org\/10.1016\/s0889-8529(02)00008-7.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2810_CR71","doi-asserted-by":"publisher","unstructured":"Program TBCDS. The Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmaco Ther. 1972;13:694\u20138. https:\/\/doi.org\/10.1002\/cpt1972135part1694.","DOI":"10.1002\/cpt1972135part1694"},{"key":"2810_CR72","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/s0924-9338(99)80685-3","volume":"13","author":"L Kessing","year":"1998","unstructured":"Kessing L. Validity of diagnoses and other clinical register data in patients with affective disorder. Eur Psychiatry. 1998;13:392\u20138. https:\/\/doi.org\/10.1016\/s0924-9338(99)80685-3.","journal-title":"Eur Psychiatry"},{"key":"2810_CR73","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/08039480510027698","volume":"59","author":"KD Jakobsen","year":"2005","unstructured":"Jakobsen KD, Frederiksen JN, Hansen T, et al. Reliability of clinical ICD-10 schizophrenia diagnoses. Nord J Psychiatry. 2005;59:209\u201312. https:\/\/doi.org\/10.1080\/08039480510027698.","journal-title":"Nord J Psychiatry"},{"key":"2810_CR74","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.4065\/81.10.1361","volume":"81","author":"TP Warrington","year":"2006","unstructured":"Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81:1361\u20137. https:\/\/doi.org\/10.4065\/81.10.1361.","journal-title":"Mayo Clin Proc"}],"updated-by":[{"DOI":"10.1186\/s12888-020-02842-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000}}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02810-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02810-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T23:13:05Z","timestamp":1629414785000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02810-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2810"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02810-x","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12888-020-02842-3","asserted-by":"object"}]},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"20 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via the original article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The use of data from the registers was approved by the Danish Data Protection Agency, the Danish National Board of Health and Statistics Denmark. According to Danish law, approval by the Ethics Committee and written informed consent were not required for register-based projects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CM Bulik is a grant recipient from and a Scientific Advisory Board member for Shire, consultant for Idorsia and received royalties from Pearson. The other authors have no potential conflicts of interest to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"411"}}